FibroBiologics ups ATM offering to $7.5M; 71,830 shares sold to date

FibroBiologics, Inc.

Increased maximum aggregate offering price under ATM facility to $7.5 million.
71,830 shares of common stock sold to date under Sales Agreement with H.C. Wainwright & Co.
ATM offering uses existing S-3 shelf registration (effective Feb 10, 2025); prospectus supplement filed May 5, 2026.
Legal opinion and consent of Sichenzia Ross Ference Carmel LLP filed as exhibits.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

FibroBiologics, Inc. entered into At The Market Offering Agreement with H.C. Wainwright & Co., LLC (effective 2026-05-01).

Action: entry
Agreement: atm program
Counterparty: H.C. Wainwright & Co., LLC
Effective: 2026-05-01

Exact text from the filing

on May 1, 2026, FibroBiologics, Inc. (the “Company”) entered into that certain At The Market Offering Agreement (the “Sales Agreement”) with H.C. Wainwright & Co., LLC (the “Sales Agent”)

View on SEC.gov

301 material agreements filed in the last 30 days. Browse all material agreements →

FibroBiologics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-207530

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.